112 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
49
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
47
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Jagiellonian University Medical College
38
Tactical Approaches to Interconverting GPCR Agonists and Antagonists.
University of Minnesota
12
Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.
Uppsala University
2
Imidazopyridines as a source of biological activity and their pharmacological potentials-Infrared and Raman spectroscopic evidence of their content in pharmaceuticals and plant materials.
Wroclaw University of Economics
4
Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands.
Uppsala University
1
Synthesis and evaluation of isoleucine derived angiotensin II AT(2) receptor ligands.
Uppsala University
129
Synopsis of some recent tactical application of bioisosteres in drug design.
Bristol Myers Squibb
39
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity rela
Pfizer
28
Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.
Uppsala University
13
Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT2 receptor.
Uppsala University
4
Design, synthesis, and incorporation of a beta-turn mimetic in angiotensin II forming novel pseudopeptides with affinity for AT1 and AT2 receptors.
Uppsala University
7
Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity.
Uppsala University
95
Designed multiple ligands. An emerging drug discovery paradigm.
Organon Laboratories
8
New selective AT2 receptor ligands encompassing a gamma-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonists.
Uppsala University
4
AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics.
Uppsala University
13
Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.
Uppsala University
7
A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II.
Uppsala University
15
Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity.
Neogenesis
49
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Dupont Pharmaceuticals
16
1,4-substituted indoles: a potent and selective class of angiostensin II receptor antagonists
TBA
13
Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.
Beijing Institute of Technology
19
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.
Pfizer
64
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
The M. S. University of Baroda
12
The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists
TBA
5
L-162,389: a potent orally active angiotensin II receptor antagonist with balanced affinity to both AT1 and AT2 receptor subtypes
TBA
27
4,5-Dihydro-4-oxo-3H-imidazo[4,5-c]pyridines: potent arylacetic acid-derived AT1 antagonists with improved affinity for the AT2 receptor
TBA
21
Balanced AT1 and AT2 angiotensin II antagonists. II. Potent 5 α-hydroxyacid imidazolyl biphenyl sulfonylureas
TBA
16
AT1 selective angiotensin II antagonists with phenoxyphenylacetic acid as a biphenyl replacement part I
TBA
27
α-Phenoxyphenylacetic acid derived angiotensin II antagonists with low nanomolar AT1/AT2 receptor subtype affinity (Part II)
TBA
4
Substituted 1,3-benzodioxole & 1,3-benzodithiole -2- carboxylates and their tetrazole analogs with potent binding affinity to the angiotensin II AT1 receptor
TBA
18
Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the AT1 and AT2 subtypes
TBA
23
Development of angiotensin II antagonists with equipotent affinity for human AT1 and AT2 receptor subtypes.
TBA
61
Balanced angiotensin II receptor antagonists. III. The effects of substitution at the imidazole 5-position.
TBA
34
Balanced angiotensin II receptor antagonists. II.1,2 4-aminomethyl- and acylaminomethylimidazoles
TBA
23
Balanced angiotensin II receptor antagonists. I. The effects of biphenyl “ortho”-substitution on AT1/AT2 affinities
TBA
27
A new class of balanced AT1/AT2 angiotensin II antagonists: quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalities
TBA
18
Quinazolinone Biphenyl Acylsulfonamides: A potent new class of angiotensin-II receptor antagonists
TBA
25
Potent imidazole angiotensinII antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacements
TBA
20
Tetrahydroisoquinoline derivatives with AT2-specific angiotensin II reception binding inhibitory activity
TBA
4
Synthesis of new imidazo[1,2-b]pyridazine isosteres of potent imidazo[4,5-b]pyridine angiotensin II antagonists
TBA
12
Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors
TBA
12
Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamide
TBA
1
4,5,6,7-Tetrahdryo-8-oxo-cycloheptimidazoles: a new class of potent non-peptide angiiotensin II receptor antagonists
TBA
28
Synthesis and structure-activity relationships of a novel series of non-peptide AT2-selective angiotensin II receptor antagonists
TBA
8
Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.
Merck Research Laboratories
9
Synthesis and Pharmacological Characterization of Fluorescent Ligands Targeting the Angiotensin II Receptors Derived from Agonists, β-Arrestin-Biased Agonists, and Antagonists.
Universite de Lorraine
9
A perspective on the development of small molecular neprilysin inhibitors (NEPi) with emphasis on cardiorenal disease.
Birla Institute of Technology and Sciences Pilani
8
The U.S. FDA approved cardiovascular drugs from 2011 to 2023: A medicinal chemistry perspective.
Sichuan University
22
Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways.
Institute of Respiratory Health
19
N-(Heteroaryl)thiophene sulfonamides as angiotensin AT2 receptor ligands.
Uppsala University
22
Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships.
Uppsala University
10
A concise review of recent advances in anti-heart failure targets and its small molecules inhibitors in recent years.
University of Electronic Science and Technology of China
26
Pseudoprolines as stereoelectronically tunable proline isosteres.
Bristol Myers Squibb
23
2-Alkyl substituted benzimidazoles as a new class of selective AT2 receptor ligands.
Uppsala University
31
Angiotensin II AT2 receptor ligands with phenylthiazole scaffolds.
Uppsala University
21
First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo.
Uppsala University
10
Using conformational constraints at position 6 of Angiotensin II to generate compounds with enhanced AT2R selectivity and proteolytic stability.
Vrije Universiteit Brussel
12
N-(Methyloxycarbonyl)thiophene sulfonamides as high affinity AT2 receptor ligands.
Uppsala University
11
The Other Angiotensin II Receptor: AT
Centre Hospitalier Universitaire Vaudois (Chuv) and University of Lausanne (Unil
24
Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.
Washington University
15
Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.
Searle
29
Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.
Merck Research Laboratories
29
Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.
Merck Research Laboratories
22
A novel series of selective, non-peptide inhibitors of angiotensin II binding to the AT2 site.
Dupont Pharmaceuticals
13
(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.
Merck Research Laboratories
9
A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor.
Merck Research Laboratories
10
Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine derivatives.
E. Merck
1
Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
China Pharmaceutical University
101
Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
Merck Research Laboratories
19
Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.
Beijing Institute of Technology
43
Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.
Carpibem
8
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
Merck Research Laboratories
44
Triazolinone biphenylsulfonamides as angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes.
Merck Research Laboratories
18
Balanced AT1/AT2 receptor antagonists. 4. XR510 and related 5-(3-amidopropanoyl)imidazoles possessing equal affinity for the AT1 and AT2 receptors.
Dupont Pharmaceuticals
3
Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonists.
Warner-Lambert
54
Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.
Merck Research Laboratories
11
Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction.
Universitaire Vaudois
14
1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.
Smithkline Beecham Pharmaceuticals
5
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
Windtree Therapeutics
65
COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS
Avanti Biosciences
28
Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
Iteos Therapeutics
4
Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.
Universitätsklinikum Frankfurt
4
Substituted indazole derivatives active as kinase inhibitors
Nerviano Medical Sciences
16
Thermodynamics of hydrogen bond and hydrophobic interactions in cyclodextrin complexes.
Nih
17
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.
Duquesne University